Expert Point of View: Jean-Yves Pierga, MD


Get Permission

Formal discussant of the MISSION trial, Jean-Yves Pierga, MD, Institut Curie, Paris, said that it is one of several studies to show no clear benefit in overall survival for the addition of a tyrosine kinase inhibitor targeting angiogenesis in advanced non–small cell lung cancer.

Dr. Pierga noted that findings of the biomarker study from MISSION are not in line with other studies. He commented, “In fact, clinical results [of studies of sorafenib and EGFR as a biomarker] are puzzling. There is no clear confirmation that EGFR status is relevant,” he said. ■

Disclosure: Dr. Pierga reported no potential conflicts of interest.


Related Articles

Sorafenib Fails to Improve Survival as Third- or Fourth-line Treatment of Advanced Non–Small Cell Lung Cancer

Third- or fourth-line therapy with sorafenib (Nexavar) failed to extend overall survival in patients with advanced non–small cell lung cancer (NSCLC), according to the main results of the phase III MISSION trial. However, a post hoc biomarker analysis of MISSION suggested that patients with...


Advertisement

Advertisement



Advertisement